Trial Profile
Safety of patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms REGATE
- Sponsors Roche
- 15 Nov 2023 Results assessing the incidence and risk factors of cancer among rheumatoid arthritis patients treated with tocilizumab and followed for five years in the French registry (REGATE), which assessed the effectiveness and safety of tocilizumab, were presented at the ACR Convergence 2023.
- 03 Sep 2020 Results assessing occurrence of major cardiovascular events and changes in cholesterol levels in rheumatoid arthritis patients who received tocilizumab, published in the Clinical and Experimental Rheumatology.
- 20 Jan 2020 Results (n=167) assessing frequency and risk factors of postoperative complications in rheumatoid arthritis patients treated with tocilizumab, published in the Clinical and Experimental Rheumatology.